Recursion reported Q4 2025 total revenue of USD 35.5 million (vs. USD 4.5 million a year earlier) and FY 2025 total revenue of USD 74.7 million (vs. USD 58.8 million). Q4 2025 net loss was USD 108.1 million, and FY 2025 net loss was USD 644.8 million. Cash, cash equivalents and restricted cash totaled USD 753.9 million at Dec. 31, 2025, with Recursion stating its expected cash runway extends into early 2028; FY 2025 net cash used in operating activities was USD 371.8 million and FY 2025 cash operating expense (non-GAAP) was USD 399.2 million. On business updates, Recursion highlighted positive preliminary Phase 2 results for REC-4881 in familial adenomatous polyposis (FAP), including 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks (n=12), with 82% maintaining durable reductions after 12 weeks off therapy and a 53% median reduction from baseline. The company also said it achieved a fifth Sanofi milestone in February 2026 for a USD 4 million payment, bringing total payments received from the Sanofi partnership to USD 134 million to date, and reported USD 753.9 million in cash and cash equivalents while guiding 2026 cash operating expense (excluding partnership inflows and transaction costs) to be less than USD 390 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602250630PRIMZONEFULLFEED9660730) on February 25, 2026, and is solely responsible for the information contained therein.